Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Magnesium

Cramps, Calm, and Cautious Evidence

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

18 human trials, about 24 studies, Mixed trials; intake-shortfall surveys. The written rationale for this grade is still being prepared.

FDA
A supplement; magnesium sulfate is also a hospital drug for specific obstetric uses
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Oral magnesium is generally well tolerated, and its most common side effect from supplements is diarrhea, sometimes with nausea or abdominal cramping; in the pregnancy leg-cramp trials, gastrointestinal effects were reported by roughly 11 to 37 percent of those taking it. The supplemental upper limit for adults, including in pregnancy, is 350 mg per day, which applies to supplements and magnesium-containing medications but not to magnesium from food. People with impaired kidney function should be cautious, because reduced clearance raises the risk of toxicity. Because the routine-supplementation evidence for symptoms like cramps is mixed, expectations should stay modest. Intravenous magnesium sulfate used in hospital is an entirely separate medical treatment and is not a substitute for or the same as a supplement. Decisions about magnesium supplementation in pregnancy or postpartum, including dose and whether it is appropriate at all, should be made with an obstetric provider, midwife, or pharmacist who knows the individual pregnancy.

Magnesium is an essential mineral, and US dietary intake in pregnancy is frequently short of the recommended 350 to 360 mg per day, with more than half of pregnant women eating less than the estimated average requirement. Oral magnesium supplements are popular for pregnancy leg cramps and sleep, but the trial evidence for routine supplementation is thin: two Cochrane reviews find the data low in certainty and inconsistent, including for cramps. The one thing that matters most to get right is that an oral magnesium pill is not the same as intravenous magnesium sulfate. Magnesium sulfate given in hospital is an established, evidence-based obstetric medicine used to prevent seizures in pre-eclampsia and to protect the preterm fetal brain, and it belongs to a different world from a supplement. Attention to dietary intake is reasonable; expectations for a supplement solving symptoms should be modest.

Widely taken for leg cramps and sleep, often below the recommended intake to begin with, but the routine-supplementation evidence is thinner than the popularity suggests.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Covering a common dietary shortfall, since more than half of pregnant women eat below the estimated average requirement
  • Popularly used for pregnancy leg cramps and sleep, though the supplement trial evidence is mixed and low certainty
  • Supporting normal muscle, nerve, and blood-sugar function as an essential mineral
  • Repletion where intake is documented to be low, alongside a magnesium-rich diet

What people get wrong

  • Often saidMagnesium supplements reliably cure pregnancy leg cramps.

    ActuallyThe dietary shortfall is real and some people report relief, but the 2020 Cochrane review of leg-cramp interventions (8 trials, 576 women) found the results inconsistent and the certainty low to very low, and concluded it is unclear whether the supplement effectively treats pregnancy cramps.

  • Often saidTaking a magnesium supplement is the same as the magnesium given in the hospital.

    ActuallyIt is not. Intravenous magnesium sulfate is a controlled hospital medication for preventing seizures in pre-eclampsia and for fetal neuroprotection in preterm birth, dosed and monitored by clinicians. It is unrelated to an over-the-counter magnesium pill and should never be conflated with one.

  • Often saidRoutine magnesium supplementation improves pregnancy outcomes for everyone.

    ActuallyThe 2014 Cochrane review pooling 10 trials in 9,090 women found no significant effect on perinatal mortality, small-for-gestational-age, or pre-eclampsia, and restricting to the two higher-quality trials removed even the apparent secondary benefits.

Who profits, and who pushes back

  • US mineral-intake analyses

    endorsesPrenatal mineral reviews

    US dietary intake of several minerals is often below the RDA, especially iodine and magnesium, supporting attention to magnesium intake in pregnancy.

  • Routine-supplementation trial evidence

    mixedMixed-results literature

    Evidence that routine magnesium supplementation improves pregnancy outcomes, including leg cramps, is limited and inconsistent, with no clear conclusion.

  • Postpartum-nutrition clinicians

    endorsesRepletion-focused practice

    With 18 to 43% of postpartum women magnesium-deficient and links to mood, sleep, and that "wired but exhausted" feeling, magnesium is a reasonable repletion focus.

  • Obstetric pharmacology

    caveatsOn magnesium sulfate

    Magnesium sulfate is an important hospital treatment for preeclampsia seizure prevention and preterm fetal neuroprotection, but it is a drug intervention distinct from dietary supplementation.

Where the research comes from

Most of the published research on this comes from one place. 60% of it is from US below RDA. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
US below RDA60%
Adequate40%

Research published from: Global.

How we got here

Magnesium's role as an essential mineral was worked out through the 19th and 20th centuries, and its dramatic clinical story runs through obstetrics rather than the supplement aisle. Physicians in the early 20th century, drawing on earlier European and North American practice, established intravenous and intramuscular magnesium sulfate for controlling and preventing eclamptic seizures, and this became standard obstetric care worldwide long before it was tested in a large randomized trial. The international Magpie trial, coordinated from Oxford and run across 33 countries including many in Africa, Asia, and Latin America, confirmed the seizure-prevention benefit in 2002. In the 2000s and 2010s, trials in Australia, the United States, and Europe extended magnesium sulfate to protecting the preterm fetal brain. Oral magnesium supplements, by contrast, grew popular for leg cramps and sleep during the 2010s and 2020s faster than the supporting trial evidence, which has stayed mixed. The gap between how much magnesium the modern diet supplies and how much is recommended is old and well documented.

  1. Early 20th c.Parenteral magnesium sulfate adopted in obstetrics to control and prevent eclamptic seizures, becoming standard care internationally
  2. 1995First of the randomized trials later pooled for fetal neuroprotection begins
  3. 1998-2001Magpie trial enrolls 10,141 women with pre-eclampsia across 175 hospitals in 33 countries
  4. 2002Magpie results (Lancet) show magnesium sulphate more than halves the risk of eclampsia
  5. 2010ACOG committee opinion supports magnesium sulfate before anticipated early preterm birth for fetal neuroprotection
  6. 2014Cochrane review of oral magnesium supplementation in pregnancy (10 trials, 9,090 women) finds insufficient high-quality evidence of benefit
  7. 2020Cochrane review of leg-cramp interventions finds oral magnesium evidence inconsistent and low certainty
  8. 2024Updated Cochrane neuroprotection review (6 RCTs, 5,917 participants) reports high-certainty reduction in cerebral palsy with antenatal magnesium sulphate

At a glance

Pregnancy RDA
350-360 mg/day
US intake
Often below RDA
Postpartum deficient
18-43%
Hospital use
Mag sulfate (distinct)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Magnesium. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources